



EFW

CASE PH 7257A CIP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Debra A. Wojcik
Type or print name

Debra A. Wojcik
Signature

June 21, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROBICHAUD ET AL.

APPLICATION NO: 10/784,064

FILED: FEBRUARY 20, 2004

FOR: SUBSTITUTED PYRIDOINDOLES AS SEROTONIN AGONISTS
AND ANTAGONISTS

Mail Stop **Box Amendment**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 10/026,611 filed December 19, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-6270

Date:

6/2/04




Sammy G. Duncan Jr. Ph.D.
Attorney for Applicants
Reg. No. 46,675

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PH 7257A CIP
APPLICATION NO.
10/784,064
APPLICANT
ROBICHAUD ET AL.
FILING DATE
FEBRUARY 20, 2004

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	3,299,078	1/17/67	Pachter			
	AB	3,914,421	10/21/75	Rajogopalan			
	AC	4,013,652	3/22/77	Rajogopalan			
	AD	4,088,647	5/9/78	Glushkov et al			
	AE	4,115,577	9/19/78	Rajogopalan			
	AF	4,183,936	1/15/80	Rajogopalan			
	AG	4,219,550	8/26/80	Rajogopalan			
	AH	4,238,607	12/9/80	Rajogopalan			
	AI	4,997,831	3/5/91	Bays et al.			
	AJ	5,100,884	3/31/92	Hamminga et al.			
	AK	5,223,625	6/29/93	Van Wijngaarden et al.			
	AL	5,328,905	7/12/94	Hamminga et al.			
	AM	6,407,092	6/18/02	Hester et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AN	2213283	2/8/74	FR			<input type="checkbox"/>	<input type="checkbox"/>
	AO	0725068	8/7/96	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AP	2,011,107	8/31/91	CA			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	0064899	11/2/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AR	0077001	12/21/00	WO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AS	Hoyer, D. et al., "VII International Union of Pharmacology Classification of Receptors...", Pharmacological Reviews, Vol. 46, No. 2, June 1, 1994, pp. 157-203 XP000604197
	AT	Jenck, F. et al., "The Role of 5-HT _{2C} Receptors in Affective Disorders", Exp. Opin. Ther. Patents, Vol. 7, No. 10, 1998, pp. 1587-1599 XP002210253
	AU	Martin, J.R. et al., "5-HT _{2C} Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential", J. Pharmacol. Exp. Ther., Vol. 286, No. 2, August 1996, pp. 913-924 XP00221024

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.